BRINGING HEALTH INSIGHT
Our pipeline of novel therapies, which is built on our RBP4 (Retinol Binding Protein 4) IP Portfolio, is focused on meeting the unmet needs of patients suffering from blindness, liver disease and diabetes.
Novel Therapy for
UNMET MEDICAL NEED
Belite Bio™ is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy (GA) in advanced dry AMD and autosomal recessive Stargardt disease, type 1, or STGD1.
Our lead candidate Tinlarebant, developed from our RBP4 intellectual property portfolio, is a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA. We’re currently conducting a two-year Phase 2 study and are enrolling patients in a two-year Phase 3 study (DRAGON) of Tinlarebant in adolescent STGD1 subjects and plan to begin enrolling patients in a two-year Phase 3 study (PHOENIX) of Tinlarebant in Geographic Atrophy (GA) in mid-2023. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S. and Orphan Drug Designation in the U.S., and Europe for the treatment of STGD1.
Bringing Hope to
Dry AMD / Stargardt Disease
Blocking the Path to
Non-Fatty Liver Disease / Type 2 Diabetes
Select Your Preferred Language:
Tinlarebant (LBS-008) – Phase 3 trial for Geographic Atrophy (the “Phoenix” trial)
Recruitment Status : Recruiting
Tinlarebant (LBS-008) – Phase 3 trial for Stargardt Disease (the “Dragon” trial)
Recruitment Status : Active: not recruiting
This trial is to assess the efficacy and safety of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease.
Tinlarebant (LBS-008) – Phase 1b/2 trial for Stargardt Disease
Recruitment Status : Active, not recruiting
This Phase 1b trial is to identify the optimal dose of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease. The Phase 1b trial is extended to a two year Phase 2 trial in assessing the safety and efficacy of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease.